<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05053334</url>
  </required_header>
  <id_info>
    <org_study_id>BP11-101</org_study_id>
    <nct_id>NCT05053334</nct_id>
  </id_info>
  <brief_title>Biosimilar Study Comparing PK, PD, Safety and Immunogencity of BP11 With US Licensed Xolair and EU Approved Xolair</brief_title>
  <official_title>A Randomized Phase I, Double-Blinded, Parallel Comparative Assessment of PK, PD, Safety, and Immunogenicity of BP11 Versus US-Licensed Xolair® and EU Approved-Xolair® Following a Single 150 mg Dose SC Administration in Healthy Male Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Syneos Health</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>CuraTeQ Biologics Private Ltd.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Syneos Health</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      A single dose, double blind comparative trial to assess the pharmacokinetics,&#xD;
      pharmacodynamics, safety and immunogenicity of 3 different products (BP11, US-Xolair and&#xD;
      EU-Xolair) containing 150mg of Omalizumab as subcutaneous injection in healthy male&#xD;
      volunteers.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study will be conducted at 2 sites in New Zealand.&#xD;
&#xD;
      A total of 165 healthy male subjects (55 subjects per arm) who meet the required entry&#xD;
      criteria will be randomly assigned to one of 3 treatment groups in a 1:1:1 ratio to receive a&#xD;
      single SC injection of either BP11, EU-Xolair, or US-Xolair.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 1, 2021</start_date>
  <completion_date type="Anticipated">October 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">October 1, 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To evaluate pharmacokinetic (PK) similarity of BP11 with US-Xolair and EU-Xolair and between US-Xolair and EU-Xolair</measure>
    <time_frame>Upto 127 Days</time_frame>
    <description>AUC0-inf will be evaluated</description>
  </primary_outcome>
  <primary_outcome>
    <measure>To evaluate PK similarity of BP11 with US-Xolair and EU-Xolair and between US-Xolair and EU-Xolair</measure>
    <time_frame>Upto 127 Days</time_frame>
    <description>Cmax will be evaluated</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>To assess and compare non-primary PK parameters of BP11 with US-Xolair and EU-Xolair</measure>
    <time_frame>Upto 127 Days</time_frame>
    <description>AUC0-t</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To assess and compare non-primary PK parameters of BP11 with US-Xolair and EU-Xolair</measure>
    <time_frame>Upto 127 Days</time_frame>
    <description>Vd</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To assess and compare non-primary PK parameters of BP11 with US-Xolair and EU-Xolair</measure>
    <time_frame>Upto 127 Days</time_frame>
    <description>Tmax, T½</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To assess and compare pharmacodynamics (PD) of BP11 with US-Xolair and EU-Xolair</measure>
    <time_frame>Upto 127 Days</time_frame>
    <description>Free IgE levels will be assessed</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To assess and compare pharmacodynamics (PD) of BP11 with US-Xolair and EU-Xolair</measure>
    <time_frame>Upto 127 Days</time_frame>
    <description>Total IgE levels will be assessed</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety &amp; tolerability of BP11 with US-Xolair and EU-Xolair</measure>
    <time_frame>Upto 127 Days</time_frame>
    <description>Assessment of Vital signs-Blood pressure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety &amp; tolerability of BP11 with US-Xolair and EU-Xolair</measure>
    <time_frame>Upto 127 Days</time_frame>
    <description>Assessment of Vital signs-Pulse rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety &amp; tolerability of BP11 with US-Xolair and EU-Xolair</measure>
    <time_frame>Upto 127 Days</time_frame>
    <description>Assessment of Vital signs-Body temperature</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety &amp; tolerability of BP11 with US-Xolair and EU-Xolair</measure>
    <time_frame>Upto 127 Days</time_frame>
    <description>Assessment of Vital signs-Respiratory rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety &amp; tolerability of BP11 with US-Xolair and EU-Xolair</measure>
    <time_frame>Screening, Pre-dose (within 1 hour of drug administration) and post dose on day 3)</time_frame>
    <description>Normal 12 Lead ECG (Ventricular rate)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety &amp; tolerability of BP11 with US-Xolair and EU-Xolair</measure>
    <time_frame>Screening, Pre-dose (within 1 hour of drug administration) and post dose on day 3)</time_frame>
    <description>Normal 12 Lead ECG (PR interval)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety &amp; tolerability of BP11 with US-Xolair and EU-Xolair</measure>
    <time_frame>Screening, Pre-dose (within 1 hour of drug administration) and post dose on day 3)</time_frame>
    <description>Normal 12 Lead ECG (QRS complex)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety &amp; tolerability of BP11 with US-Xolair and EU-Xolair</measure>
    <time_frame>Screening, Pre-dose (within 1 hour of drug administration) and post dose on day 3)</time_frame>
    <description>Normal 12 Lead ECG (QT interval and QT interval corrected for heart rate using Bazett's formula)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety &amp; tolerability of BP11 with US-Xolair and EU-Xolair</measure>
    <time_frame>Pre-dose(0hour or within 1 hour prior of drug administration), post dose at 6hours, 12 hours and 24hours.</time_frame>
    <description>Assessment of injection site reaction</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">165</enrollment>
  <condition>Healthy Volunteers</condition>
  <arm_group>
    <arm_group_label>BP11 (Proposed biosimilar)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subcutaneous injection of Omalizumab developed by CuraTeQ.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>US-Xolair</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subcutaneous injection of Omalizumab licensed for use in USA</description>
  </arm_group>
  <arm_group>
    <arm_group_label>EU-Xolair</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subcutaneous injection of Omalizumab approved for use in Europe.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Omalizumab Prefilled Syringe</intervention_name>
    <description>150mg/ml of Omalizumab prefilled syringe</description>
    <arm_group_label>BP11 (Proposed biosimilar)</arm_group_label>
    <arm_group_label>EU-Xolair</arm_group_label>
    <arm_group_label>US-Xolair</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Signed and dated written informed consent prior to any study-specific procedures,&#xD;
             ability to understand, and willingness to comply with the study procedures,&#xD;
             restrictions, and requirements as judged and confirmed by the Investigator.&#xD;
&#xD;
          2. Healthy adult male subjects, 18 to 55 years (both inclusive) of age at the time of&#xD;
             signing informed consent.&#xD;
&#xD;
          3. Subjects who are considered healthy as determined by clinically acceptable findings of&#xD;
             hematology, clinical chemistry, coagulation profile, urinalysis, and 12-lead ECG as&#xD;
             per investigator's discretion.&#xD;
&#xD;
          4. Subject must agree to use a highly effective contraception as detailed in Appendix&#xD;
             1(Section 13.1) during the study period (starting from screening visit) and until 9&#xD;
             months after administration of BP11, Xolair® -EU or Xolair® -US by agreeing to use&#xD;
             (with their female partner if she is of childbearing potential) 2 acceptable forms of&#xD;
             contraception.&#xD;
&#xD;
          5. Subjects must refrain from donating sperm or fathering a child during the study period&#xD;
             (starting from screening visit) and until 9 months after administration of BP11,&#xD;
             Xolair®-EU or Xolair®-US administration by agreeing to use (with their female partner&#xD;
             if she is of childbearing potential) 2 acceptable forms of contraception.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Known history of hypersensitivity or allergic reactions to omalizumab or any of its&#xD;
             excipients.&#xD;
&#xD;
          2. History of cardiovascular, hepatic, ophthalmic, pulmonary, neurological, metabolic,&#xD;
             hematological, gastrointestinal, endocrine, immunological, psychiatric or any other&#xD;
             disease which in the opinion of the Investigator would make the subject inappropriate&#xD;
             for study participation.&#xD;
&#xD;
          3. Abnormal and clinically relevant (in the opinion of the Investigator) vital signs,&#xD;
             ECG, history of angina, exertional dyspnea, orthopnea, congestive heart failure, or&#xD;
             myocardial infarction.&#xD;
&#xD;
          4. Major surgery or major trauma within past one year of screening or anticipated need&#xD;
             for any surgery during the study duration.&#xD;
&#xD;
          5. Difficulty in blood sampling or difficulty in accessibility of veins.&#xD;
&#xD;
          6. History of significant alcohol abuse within 1 years prior to screening or regular use&#xD;
             of alcohol within 6 months prior to the screening visit (more than 14 units of alcohol&#xD;
             per week [1 unit = 150 mL of wine, 360 mL of beer, or 45 mL of 40% alcohol]).&#xD;
&#xD;
          7. History of drug abuse within 1 year prior to screening or recreational use of soft&#xD;
             drugs (such as marijuana) within 1 month or hard drugs (such as cocaine, phencyclidine&#xD;
             [PCP], crack, opioid derivatives including heroin, and amphetamine derivatives) within&#xD;
             3 months prior to screening.&#xD;
&#xD;
          8. Subjects with positive drug test at screening or admission.&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Disha Dadke, Dr.</last_name>
    <phone>+91 8455255222</phone>
    <email>Disha.Dadke@curateqbio.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Arpit Kumar Prajapati, Dr.</last_name>
    <email>Arpitkumar.Prajapati@curateqbio.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Auckland Clinical Studies Ltd (NZCR OpCo Limited)</name>
      <address>
        <city>Grafton</city>
        <state>Auckland</state>
        <zip>1010</zip>
        <country>New Zealand</country>
      </address>
    </facility>
    <contact>
      <last_name>Leanne Barnett, Dr</last_name>
      <phone>093733474</phone>
      <email>leanne.barnett@nzcr.co.nz</email>
    </contact>
    <investigator>
      <last_name>Leanne Barnett, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Christchurch Clinical Studies Trust Ltd (NZCR OpCo Limited)</name>
      <address>
        <city>Antigua Street</city>
        <state>Christchurch</state>
        <zip>8011</zip>
        <country>New Zealand</country>
      </address>
    </facility>
    <contact>
      <last_name>Chris Wynne, Dr.</last_name>
      <phone>033729477</phone>
      <email>Chris.Wynne@nzcr.co.nz</email>
    </contact>
    <investigator>
      <last_name>Chris Wynne, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>New Zealand</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>August 22, 2021</study_first_submitted>
  <study_first_submitted_qc>September 21, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">September 22, 2021</study_first_posted>
  <last_update_submitted>September 24, 2021</last_update_submitted>
  <last_update_submitted_qc>September 24, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 30, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Omalizumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

